Horizon Therapeutics Public (NASDAQ:HZNP) Rating Increased to B- at TheStreet

TheStreet upgraded shares of Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) from a c+ rating to a b- rating in a research note issued to investors on Tuesday morning, TheStreetRatingsTable reports.

HZNP has been the topic of a number of other reports. Piper Sandler cut their target price on Horizon Therapeutics Public from $90.00 to $88.00 and set an overweight rating on the stock in a research report on Tuesday, October 25th. UBS Group lowered shares of Horizon Therapeutics Public from a buy rating to a neutral rating and decreased their price objective for the stock from $137.00 to $71.00 in a research note on Thursday, August 4th. Morgan Stanley cut their target price on shares of Horizon Therapeutics Public from $135.00 to $90.00 and set an overweight rating on the stock in a research note on Thursday, August 4th. HC Wainwright began coverage on Horizon Therapeutics Public in a report on Tuesday, November 1st. They issued a neutral rating and a $74.00 target price on the stock. Finally, StockNews.com raised shares of Horizon Therapeutics Public from a hold rating to a buy rating in a research report on Thursday, November 3rd. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of Moderate Buy and an average price target of $105.00.

Horizon Therapeutics Public Trading Up 0.3 %

Horizon Therapeutics Public stock opened at $77.53 on Tuesday. The firm has a market cap of $17.57 billion, a price-to-earnings ratio of 31.77, a price-to-earnings-growth ratio of 1.54 and a beta of 1.09. Horizon Therapeutics Public has a 1 year low of $57.84 and a 1 year high of $117.49. The firm’s 50 day moving average price is $67.51 and its two-hundred day moving average price is $74.32. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.74 and a current ratio of 3.96.

Institutional Trading of Horizon Therapeutics Public

Several large investors have recently modified their holdings of HZNP. Vanguard Group Inc. boosted its holdings in Horizon Therapeutics Public by 1.7% during the third quarter. Vanguard Group Inc. now owns 21,276,662 shares of the biopharmaceutical company’s stock valued at $1,316,812,000 after acquiring an additional 354,287 shares during the period. BlackRock Inc. increased its position in Horizon Therapeutics Public by 7.0% during the third quarter. BlackRock Inc. now owns 15,619,023 shares of the biopharmaceutical company’s stock worth $966,660,000 after acquiring an additional 1,020,576 shares during the period. Capital International Investors acquired a new position in Horizon Therapeutics Public during the 1st quarter valued at $744,453,000. JPMorgan Chase & Co. boosted its holdings in Horizon Therapeutics Public by 8.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,652,529 shares of the biopharmaceutical company’s stock valued at $530,605,000 after purchasing an additional 537,550 shares during the period. Finally, Paulson & CO. Inc. grew its position in Horizon Therapeutics Public by 10.4% in the 2nd quarter. Paulson & CO. Inc. now owns 6,199,000 shares of the biopharmaceutical company’s stock worth $494,432,000 after purchasing an additional 585,000 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Further Reading

Analyst Recommendations for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.